E.g., 08/07/2022
E.g., 08/07/2022
Title Category Credit Event date Price
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Update Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advances in Immuno-Oncology in Urothelial Carcinoma Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will review the important and newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive (HSPC) and Castration-Resistant Prostate Cancer (CRPC). This includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of M1 HSPC and non-metastatic MO CRPC. Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines.
Bladder Cancer Treatment Dilemmas: The Cases You Face and What To Do about Them Webcast (2022)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Update recent AUA, European Association of Urology (EAU), and National Comprehensive Cancer Network (NCCN®) Guidelines® for the quickly evolving field of bladder cancer. Case scenarios will outline important changes as well as concepts essential in providing evidence-based care.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:AstraZenecaBristol Myers SquibbMerck & Co., Inc.Pfizer, Inc.
Case-Based Discussion: BCR and Novel Pet Imaging & M0 CRPC Podcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC).
Case-Based Discussion: Early M1 CRPC and Advanced M1 CRPC Podcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC).
Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docetaxel, Neuroendocrine Cancer and End-of-Life Care Podcast (...
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC).
Clinical Cases in Urology: Diagnosis and Treatment of Early Stage Testicular Cancer (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Cases in Urology guideline-based case scenarios were designed to help maximize the impact of the guidelines. This case will focus on the AUA Guideline, Diagnosis and Treatment of Early Stage Testicular Cancer. 
Clinical Problem Solving (CPS) Protocol: Shared Decision Making and Engaging Disparities in Prostate Cancer Care (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Engaging Disparities in Prostate Cancer Care consists of multiple educational activities featuring a variety of formats for the urologic healthcare team to reinforce the essentials of SDM to better assist high-risk patients in regards to prostate cancer screening and treatment. A live webinar, Clinical Problem Solving (CPS) Protocol, and Podcast Series will enable participants to be better prepared to apply SDM in their practice.
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer Webcast (2022)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Kidney cancer is not a single disease; it is made up of several different types of cancer, each with a different histology, a different clinical course, responding differently to therapy and caused by different genes. After completing this course, attendees be able to describe the different types of kidney cancer and the genes that cause each. They will learn how to identify the different types of inherited versus sporadic forms of kidney cancer.
Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach Webcast (2022)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 The course director will select 6 real cases from his own practice that represent challenging cases in bladder cancer and present them to his panelists. The panelists will review the available literature and formulate a treatment plan based upon the guidelines and published literature. The course director will then present the actual patient outcome and readdress the panelists with follow-up problems and questions to illustrate the many unique aspects of dealing with these patients.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:
Evolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Genetic Testing in Prostate Cancer: Clinical Implications for Early Detection and Management of Localized and Advanced Disease Webcast (2022)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of the breast cancer gene (BRCA1/2) mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease, & Castration Resistant Prostate...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
How to Safely and Properly Administer Immunotherapies Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.

Pages